Effect of serum adropin levels on circulating endothelial dysfunction biomarkers in COVID-19 patients

Basit Öğe Kaydı
dc.authorid0000-0002-9033-4236
dc.contributor.authorGunesacar, Ramazan
dc.contributor.authorEksi, Durkadin Demir
dc.contributor.authorAlpay, Ali Seydi
dc.contributor.authorHanikoglu, Ferhat
dc.contributor.authorErdogan, Haluk
dc.date.accessioned2026-01-24T12:29:18Z
dc.date.available2026-01-24T12:29:18Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractPurpose: Several studies show that the symptoms of severe COVID-19 infection reflect the clinical phenotype of endothelial dysfunction and share common pathophysiological mechanisms with endothelial dysfunction. Therefore, the aim of the study was to investigate the effect of serum adropin levels on endothelial dysfunction biomarkers and determine whether adropin could be a new biomarker for COVID-19.Materials and Methods: The study included 40 patients with mild/moderate COVID-19, 48 patients with severe/critical COVID-19, and 37 controls. Serum adropin and circulating biomarkers of endothelial dysfunction including asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), soluble intercellular adhesion molecule-1 (sICAM-1) and plasminogen activator inhibitor-1 (PAI-1) levels were determined by micro-ELISA. Results: Serum adropin levels were found to be significantly higher in COVID-19 patients (165.2 & PLUSMN;11.49 pg/ml) than in controls (85.46 & PLUSMN;12.08 pg/ml). Serum adropin levels of patients with severe/critical symptoms (194 & PLUSMN;16.23 pg/ml) were significantly higher than the patients with mild/moderate symptoms (130.6 & PLUSMN;14.53). In addition, serum ADMA, eNOS, and, ET-1 levels were significantly higher in the COVID-19 subjects (150.5 & PLUSMN;8.67 ng/ml, 172.4 & PLUSMN;14.01 pg/ml, 159.3 & PLUSMN;10.19 pg/ml, respectively) than that those in the controls (104.5 & PLUSMN;9.182 ng/ml, 141.4 & PLUSMN;17.74 pg/ml, 100.1 & PLUSMN;11.37 pg/ml, respectively). Significant positive correlations were found between adropin and ADMA, eNOS, ET-1, sICAM-1, and PAI-1 levels in the patients. Conclusion: We suggest that adropin may be a new potential biomarker for COVID-19 and an important molecule in restoring endothelial cell damage. Positive correlations between serum adropin levels and ADMA, eNOS, ET-1, sICAM-1 and PAI-1 levels in patients suggest that adropin may compensate for damage to endothelial cells.
dc.description.sponsorshipAlanya Alaaddin Keykubat University Research Fund, Antalya, Turkiye [2021-04-01-MAP13]
dc.description.sponsorship& nbsp;This study was supported by the Alanya Alaaddin Keykubat University Research Fund, Antalya, Turkiye (Project number: 2021-04-01-MAP13) .
dc.identifier.doi10.17826/cumj.1279322
dc.identifier.endpage574
dc.identifier.issn2602-3032
dc.identifier.issn2602-3040
dc.identifier.issue2
dc.identifier.startpage567
dc.identifier.trdizinid1197746
dc.identifier.urihttps://doi.org/10.17826/cumj.1279322
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1197746
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5260
dc.identifier.volume48
dc.identifier.wosWOS:001038321300028
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherCukurova Univ, Fac Medicine
dc.relation.ispartofCukurova Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectCOVID-19
dc.subjectadropin
dc.subjectendothelial dysfunction
dc.subjectbiomarkers
dc.titleEffect of serum adropin levels on circulating endothelial dysfunction biomarkers in COVID-19 patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu